[go: up one dir, main page]

AU2024212866A1 - Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent - Google Patents

Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent

Info

Publication number
AU2024212866A1
AU2024212866A1 AU2024212866A AU2024212866A AU2024212866A1 AU 2024212866 A1 AU2024212866 A1 AU 2024212866A1 AU 2024212866 A AU2024212866 A AU 2024212866A AU 2024212866 A AU2024212866 A AU 2024212866A AU 2024212866 A1 AU2024212866 A1 AU 2024212866A1
Authority
AU
Australia
Prior art keywords
psychiatric
treatment
acting
short
neurological disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024212866A
Inventor
Tiffanie BENWAY
Meghan Good
Ellen James
Zelah JOEL
Alex KELLY
Peter RANDS
Carol Routledge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybin UK Ltd
Original Assignee
Cybin UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybin UK Ltd filed Critical Cybin UK Ltd
Publication of AU2024212866A1 publication Critical patent/AU2024212866A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a dosage regimen, method for treating, delivery device or parenteral formulation for use in the treatment of a psychiatric or neurological disorder in a patient. In particular, the invention relates to the administration of a psychedelic agent.
AU2024212866A 2023-01-23 2024-01-23 Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent Pending AU2024212866A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363481040P 2023-01-23 2023-01-23
US63/481,040 2023-01-23
US202363488613P 2023-03-06 2023-03-06
US63/488,613 2023-03-06
PCT/EP2024/051569 WO2024156713A1 (en) 2023-01-23 2024-01-23 Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent

Publications (1)

Publication Number Publication Date
AU2024212866A1 true AU2024212866A1 (en) 2025-08-07

Family

ID=89723051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024212866A Pending AU2024212866A1 (en) 2023-01-23 2024-01-23 Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent

Country Status (6)

Country Link
EP (1) EP4654967A1 (en)
KR (1) KR20250136896A (en)
CN (1) CN121038789A (en)
AU (1) AU2024212866A1 (en)
IL (1) IL322260A (en)
WO (1) WO2024156713A1 (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3873883T (en) 2019-11-07 2023-03-24 Small Pharma Ltd SYNTHESIS METHOD
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc New compositions of pharmaceutical substances and preparations
PH12022553135A1 (en) 2020-05-19 2024-03-04 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
JP7567024B2 (en) 2020-08-05 2024-10-15 ユニヴェルシテートスピタル バーゼル Methods for intravenous DMT administration for DMT-assisted psychotherapy
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
AU2021334933B2 (en) 2020-08-28 2023-01-19 Cybin Uk Ltd Injectable formulation
US11000534B1 (en) * 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
WO2022082058A1 (en) * 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
IL303288A (en) 2020-12-01 2023-07-01 Small Pharma Ltd N,N-Dimethyltryptamine compounds partially or fully deuterated
WO2022117640A1 (en) 2020-12-01 2022-06-09 Small Pharma Ltd Inhalable formulations
WO2022195489A2 (en) 2021-03-15 2022-09-22 Tryp Therapeutics Inc. Improved methods for the use of psychedelics

Also Published As

Publication number Publication date
KR20250136896A (en) 2025-09-16
CN121038789A (en) 2025-11-28
IL322260A (en) 2025-09-01
WO2024156713A1 (en) 2024-08-02
EP4654967A1 (en) 2025-12-03

Similar Documents

Publication Publication Date Title
AU4743601A (en) Neutral antagonists and use thereof in treating drug abuse
JP2022188221A (en) Treatment of Thalamocortical Dysrhythmias
CA2602950A1 (en) Methods for the treatment of central nervous system injury via a tapered administration of progesterone
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
CN102811722A (en) Treatment of loss of touch with saxitoxin derivatives
MXPA04003548A (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi).
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2024010637A (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases.
AU5898798A (en) The topical use of kappa opioid agonists to treat ocular pain
AU2024242138A1 (en) Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent
WO2025019318A3 (en) Methods of treating a ras related disease or disorder
AU2024212866A1 (en) Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent
JP2016505050A5 (en)
WO2007038428A3 (en) Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds
Albright Neurosurgical treatment of spasticity: selective posterior rhizotomy and intrathecal baclofen
WO2022131919A8 (en) Acth in the treatment of an adrenocorticotropic hormone responsive pediatric disorder
Harned et al. An introduction to trialing intrathecal baclofen in patients with hemiparetic spasticity: a description of 3 cases
US11752143B2 (en) Methods of using low dose naltrexone to treat chronic pain
WO2022026762A1 (en) Apparatus, system, and method for facilitating intranasal treatment of a patient
WO2005037158A1 (en) Method for providing long-lasting pain diminishment through topical or intranasal administration of civamide
RU99123225A (en) METHOD FOR TREATING SEVERE BRONCH-OBSTRUCTIVE SYNDROME IN CHILDREN OF EARLY AGE
JP2008539265A5 (en)
Saulino et al. Intrathecal Baclofen
US20150157699A1 (en) Methods of treating psoriasis using candida antigen
JP3381198B2 (en) Use of 1,4-dihydropyridine in diabetes